Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Expression of Integrin-linked Kinase is not a Useful Prognostic Marker in Resected Hepatocellular Cancer

PONGPHOB INTARAPRASONG, KIRAN ASSI, DAVID A. OWEN, DAVID G. HUNTSMAN, STEPHEN W. CHUNG, CHARLES H. SCUDAMORE, ERIC M. YOSHIDA and BALJINDER SALH
Anticancer Research November 2007, 27 (6C) 4371-4376;
PONGPHOB INTARAPRASONG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KIRAN ASSI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAVID A. OWEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAVID G. HUNTSMAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEPHEN W. CHUNG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHARLES H. SCUDAMORE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ERIC M. YOSHIDA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BALJINDER SALH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bsalh@interchange.ubc.ca
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Hepatocellular cancer (HCC) is one of the most common malignancies worldwide, and is known to be associated with a poor prognosis. Unfortunately there are no available reliable markers of prognosis. The aim of this study was to determine whether integrin-linked kinase (ILK) expression correlates with post-resection survival from HCC. Patients and Methods: A tissue microarray was constructed using HCC samples, and immunohistochemical analysis for ILK was then carried out and scored by three independent observers. Clinical chart review was performed to determine survival parameters. Results: Of the 52 cases of HCC, 22 cases were associated with hepatitis B (HBV), 18 with hepatitis C (HCV), 2 with HBV and HCV co-infection; 81% of all patients were male and 19% female. Western immunoblotting showed a highly significant correlation between levels of expression of ILK and ser473-PKB phosphorylation, both in control and tumor sections (Spearman rank correlation, r=0.8155, p=0.0004), however, there was no direct correlation between the levels of expression of ILK with patient survival (log-rank test, p=0.864). Conclusion: ILK expression does not appear to have a role in predicting outcome in patients with resected HCC.

  • Integrin-linked kinase
  • hepatocellular cancer
  • tissue microarray
  • survival

Footnotes

  • Received April 25, 2007.
  • Revision received August 28, 2007.
  • Accepted October 4, 2007.
  • Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 27 (6C)
Anticancer Research
Vol. 27, Issue 6C
November-December 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Expression of Integrin-linked Kinase is not a Useful Prognostic Marker in Resected Hepatocellular Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Expression of Integrin-linked Kinase is not a Useful Prognostic Marker in Resected Hepatocellular Cancer
PONGPHOB INTARAPRASONG, KIRAN ASSI, DAVID A. OWEN, DAVID G. HUNTSMAN, STEPHEN W. CHUNG, CHARLES H. SCUDAMORE, ERIC M. YOSHIDA, BALJINDER SALH
Anticancer Research Nov 2007, 27 (6C) 4371-4376;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Expression of Integrin-linked Kinase is not a Useful Prognostic Marker in Resected Hepatocellular Cancer
PONGPHOB INTARAPRASONG, KIRAN ASSI, DAVID A. OWEN, DAVID G. HUNTSMAN, STEPHEN W. CHUNG, CHARLES H. SCUDAMORE, ERIC M. YOSHIDA, BALJINDER SALH
Anticancer Research Nov 2007, 27 (6C) 4371-4376;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
  • End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report
  • Effect of a Biweekly Dosing Schedule on Severe Neutropenia Induced by Trifluridine/Tipiracil in Colorectal Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire